Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988460 | 0.84 | GRM5 (0.59) | GRM5 | |
| SCHEMBL2201905 | 0.83 | CYP19A1 (0.52) | GRM5ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL2200888 | 0.80 | PIN1 (0.54) | GRM5ALDH1A1NPC1KMT2ASMN1; SMN2 | |
| SCHEMBL2202998 | 0.78 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9AKDM4EPLAU | |
| SCHEMBL28100881 | 0.76 | GRM5 (0.46) | GRM5ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2199009 | 0.74 | GRM5 (0.46) | GRM5ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL27676182 | 0.74 | CNR1 (0.61) | GRM5 | |
| SCHEMBL28784486 | 0.73 | KCNH2 (0.43) | ALDH1A1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4692622 | 0.71 | RXFP1 (0.47) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2203114 | 0.71 | RPA1 (0.51) | GRM5ALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| CN-101765430-A | Novel pyrazole derivatives | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | GRM5 214/4885ALDH1A1 1476/4885NPC1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.